ADRB3 and obesity disorder: The latter deserve special consideration, as improvements in the overall metabolic status—i.e., decreased triglyceridemia, and decreased obesity, with increased insulin sensitivity and/or β3-AR-mediated endocrine/paracrine signaling from adipose tissue—can greatly affect the cardiovascular system.